Only prospective studies that incorporate objective sleep data, serial cognitive evaluations during the follow-up, and biomarkers (e.g., β-amyloid or tau) can determine whether addressing sleep issues might have a genuine preventive or therapeutic effect on AD progression. This evidence concerns the gene MAPT and Alzheimer disease.